NeuralCIM: Cuba's Breakthrough Alzheimer's Treatment Now Available at La Pradera

Cuba has long been at the forefront of biopharmaceutical innovation, and the approval of NeuralCIM (NeuroEPO Plus) in March 2025 marks a significant milestone in Alzheimer's treatment.

NeuralCIM is a medication derived from Erythropoietin, a substance naturally produced by the kidneys and brain. It works by stimulating brain cell growth, reducing inflammation, prolonging the life of existing neurons, and promoting the creation of new brain cells.

The ATHENEA trial, Cuba's landmark clinical study, enrolled 170 patients and demonstrated remarkable results. At the end of one year, 54% of patients on the treatment showed improvement in their dementia symptoms, while 30% remained stable. By contrast, 85% of the placebo group experienced disease progression.

Over the past year, 52 international patients have traveled to La Pradera International Clinic in Havana to receive NeuralCIM treatment, with many showing inspiring cognitive improvements.

For international patients seeking access to this groundbreaking treatment, La Pradera International Health Center provides comprehensive care coordination, including medical evaluation, treatment administration, and ongoing monitoring.